Our Scientific Team
Our team of experienced PhD-level researchers and regulatory affairs specialists understand both the methodology and the mindset that agencies require—designing studies that deliver detailed patient insights into compelling evidence for regulatory submission.
Patient research expertise
Our scientific team understands how to design and conduct patient-focused drug development studies for compelling regulatory evidence and commercial decision-making, in alignment with client objectives and FDA-recommended guidance for patient-focused drug development. We partner with you to design studies to support clinical endpoints, labelling claims, PRO strategies, and evidence of meaningful treatment benefit. Whether you're interested in quality-of-life outcomes or caregiver burden, we work with you to deliver powerful evidence for patient-informed regulatory outcomes and market differentiation.
We put science first
Listen to our chief scientific officer, Anna Ryden (PhD), explain how we follow the rigorous scientific methodologies required for patient interviews to support regulatory submissions and labelling claims or evidence for payer authorities.
1.png)
For expert regulatory guidance
We deliver scientifically rigorous patient experience data to strengthen regulatory submissions and payer interactions.
© Copyright 2025
CLINIGMA® All rights reserved